Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21791400 | 0.78 | LMNA (0.42) | LMNAKDM4EPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14247000 | 0.78 | ALDH1A1 (0.34) | LMNAKDM4EGRM5CYP11B1CYP11B2 | |
| SCHEMBL23481093 | 0.78 | LMNA (0.34) | LMNA | |
| SCHEMBL16886099 | 0.75 | LMNA (0.32) | LMNA | |
| SCHEMBL22778456 | 0.75 | RXRA (0.33) | LMNAGRM5RXRAGRIN1GRIN2B | |
| SCHEMBL18929494 | 0.75 | LMNA (0.32) | LMNAGRM5 | |
| SCHEMBL18925719 | 0.75 | LMNA (0.32) | LMNA | |
| SCHEMBL18929491 | 0.75 | NPC1 (0.34) | LMNAKDM4EGRM5 | |
| SCHEMBL487301 | 0.75 | TSHR (0.41) | LMNAMAOADYRK1A | |
| SCHEMBL18929489 | 0.73 | CASP3 (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9795608-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| EP-2870158-B1 | 1-[4-(3-PHENOXY)-PHENYL]-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7-YL-AMINE DERIVATIVES AS BRUTON'S TYROSINE KINASE (BTK) INHIBITORS FOR THE TREATMENT OF E.G. PROLIFERATIVE DISEASES | PHARMASCIENCE INC (CA) | 2017-05-31 | — | — | EP | disclosed |
| US-20160289236-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-9447102-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2016-09-20 | — | — | US | disclosed |
| US-20150344478-A1 | PROTEIN KINASE INHIBITORS | GB005, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
| WO-2014005217-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013177668-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | LMNA 3577/4885KDM4E 4212/4885MAOA 694/4885 |
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | LMNA 4507/4885KDM4E 1783/4885MAOA 3628/4885 |
| US-20150344478-A1 | PROTEIN KINASE INHIBITORS | TEC, BTK, LCK | LMNA 4757/4885KDM4E 1534/4885MAOA 3064/4885 |
| US-20160289236-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | LMNA 4537/4885KDM4E 1712/4885MAOA 3406/4885 |
| US-20170158697-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | LMNA 4651/4885KDM4E 1655/4885MAOA 3359/4885 |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | LMNA 4795/4885KDM4E 1338/4885MAOA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.